A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)
International Journal of Radiation Oncology*Biology*Physics · 2025
DOI: 10.1016/j.ijrobp.2025.12.021 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Gargi Kothari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, Univer…. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery. Die Arbeit nennt 13 Literaturangaben. Gefördert von: Bristol-Myers Squibb Company.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Programmed cell death protein-1 inhibitors have improved metastatic non-small cell lung cancer (NSCLC) prognosis. Stereotactic ablative body radiation therapy (SABR) may enhance immunity. This study evaluated the activity and safety of adding SABR to first-line immunotherapy post chemotherapy with nivolumab for metastatic NSCLC. METHODS AND MATERIALS: NIVORAD (ALTG14/002/CT0135/TROG 16.01) randomized adults (1:2) to nivolumab 240 mg 2-weekly until disease progression or prohibitive toxicity either alone, or with single fraction SABR (18-20 Gy). Eligible patients had metastatic NSCLC, had progressed after 1-2 lines of chemotherapy, were immunotherapy-naïve, and had a disease site suitable for SABR. The primary endpoint was progression free survival (PFS) at 6 months. Secondary endpoints were objective tumor response rate, overall survival, PFS at 1 and 2 years, and adverse events (AEs). The planned sample size of 120 was to provide 80% power with a 1-sided type 1 error rate of 5% to distinguish the observed proportions alive and progression free at 6 months. The study closed early because of slow accrual. RESULTS: Fifty participants were recruited and randomly assigned to nivolumab alone (n = 16) or nivolumab plus SABR (n = 34). Baseline characteristics were balanced across treatment arms, apart from percentage of females which was higher in the control arm (56% vs 35%). Median follow-up was 26 months. PFS was similar among those assigned nivolumab plus SABR versus nivolumab alone (PFS at 6 months 49% vs 44%, hazard ratio [HR], 0.68; 95% CI, 0.36-1.27; P = .23). Objective tumor response rate (8/34[24%] vs 4/16[25%]) and overall survival (HR, 0.86; 95% CI, 0.43-1.75; P = .69) were also similar in the 2 treatment groups. Rates of serious grade 3-5 AE (12/16 (75%) vs 24/31 (77%) in experimental arm) were also similar in the 2 groups. There were 2 deaths, 1 in each treatment group (pneumonitis and respiratory failure). CONCLUSIONS: Nivolumab plus SABR demonstrated similar efficacy and safety to nivolumab alone in metastatic NSCLC progressing after chemotherapy, without increased AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- Northern Sydney Cancer Centre, Radiation Oncology Unit, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia; National Health and Medical Research Council Clinical Trials Centre, The University of…
- National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia.
- The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia; Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Centre for Medical…
- Department of Radiation Oncology, Central Adelaide Local Health Network, Adelaide, South Australia, Australia; UniSA Allied Health and Human Performance, University of South Australia, Adelaide, South Australia, Austral…
Förderung
- Bristol-Myers Squibb Company
Zitieren
APA
Kothari, G., O'Byrne, K. J., Brown, C., Stockler, M. R., Walker, M., Hardcastle, N., Kron, T., Le, H. V., Kosmider, S., Cameron, L., Lao, L., Mitchell, P., & Siva, S. (2025). A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.12.021
Vancouver
Kothari G, O'Byrne KJ, Brown C, Stockler MR, Walker M, Hardcastle N, et al. A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.12.021
BibTeX
@article{Kothari2025,
author = {Kothari, Gargi and O'Byrne, Kenneth J and Brown, Chris and Stockler, Martin R and Walker, Mariya and Hardcastle, Nicholas and Kron, Tomas and Le, Hien V and Kosmider, Suzanne and Cameron, Laird and Lao, Louis and Mitchell, Paul and Siva, Shankar},
title = {A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiation Therapy in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD)},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2025},
doi = {10.1016/j.ijrobp.2025.12.021}
}
EUVIMED